Benzinga·2025-12-09 13:16Company Insights - Ascendis Pharma A/S's New Drug Application (NDA) for TransCon CNP has had its review period extended by the FDA, with the new target action date set for February 28, 2026, due to a major amendment submitted on November 5 [2] - Ascendis Pharma's stock rose by 0.8% to close at $207.12 on Monday [6] Industry Trends - The consumer discretionary sector is showing signs of optimism, with growth expectations for the next year, as indicated by the selection of iShares US Consumer Discretionary ETF by NB Private Wealth [3] - Monolithic Power Systems Inc reported better-than-expected third-quarter results, with earnings of $4.73 per share surpassing the consensus estimate of $4.64, and sales of $737.176 million exceeding the estimate of $722.252 million [5] - Monolithic Power's shares gained 2.1% to close at $983.58 on Monday [6] Analyst Ratings - Morgan Stanley analyst Terence Flynn maintained an Overweight rating on Vertex and raised the price target from $516 to $564 [4]